Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022
November 07 2022 - 7:00AM
Business Wire
Gelesis Holdings, Inc. (NYSE:GLS) (“Gelesis” or the “Company”),
the maker of Plenity® for weight management, today announced that
the Company will report financial results for the third quarter
ended September 30, 2022, on November 14, 2022 prior to the market
open. Gelesis management will host a live conference call and
webcast at 8:30 a.m. ET on the same day to discuss the results.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221107005166/en/
Gelesis is a consumer-centered
biotherapeutics company and the maker of Plenity for weight
management. (Photo: Business Wire)
The live call can be accessed via webcast on the “Events &
Presentations” section of the Gelesis Investor Relations website at
https://ir.gelesis.com/. The webcast will also be archived and
available for replay shortly after the call has concluded. Those
who are interested in participating in the live call can dial
844-200-6205 from the U.S. and 929-526-1599 internationally, and
enter the access code 849038.
About Gelesis
Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis”) is a
consumer-centered biotherapeutics company and the maker of
Plenity®, which is inspired by nature and FDA cleared to aid in
weight management. Our first-of-their-kind non-systemic
superabsorbent hydrogels are made entirely from naturally derived
building blocks. They are inspired by the composition and
mechanical properties of raw vegetables, taken by capsule, and act
locally in the digestive system, so people feel satisfied with
smaller portions. Our portfolio includes Plenity® and potential
therapies in development for patients with Type 2 Diabetes,
Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic
Steatohepatitis (NASH), and Functional Constipation. For more
information, visit gelesis.com, or connect with us on Twitter
@GelesisInc. Plenity® is indicated to aid weight management in
adults with excess weight or obesity, a Body Mass Index (BMI) of
25–40 kg/m², when used in conjunction with diet and exercise.
Important Safety Information about Plenity
- Patients who are pregnant or are allergic to cellulose, citric
acid, sodium stearyl fumarate, gelatin, or titanium dioxide should
not take Plenity.
- To avoid impact on the absorption of medications:
- For all medications that should be taken with food, take them
after starting a meal.
- For all medications that should be taken without food (on an
empty stomach), continue taking on an empty stomach or as
recommended by your physician.
- The overall incidence of side effects with Plenity was no
different than placebo. The most common side effects were diarrhea,
distended abdomen, infrequent bowel movements, and flatulence.
- Contact a doctor right away if problems occur. If you have a
severe allergic reaction, severe stomach pain, or severe diarrhea,
stop using Plenity until you can speak to your doctor.
Rx Only. For the safe and proper use of Plenity or more
information, talk to a healthcare professional, read the Patient
Instructions for Use, or call 1-844-PLENITY.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221107005166/en/
Investors & Media: Katie Sullivan
ksullivan@gelesis.com
Gelesis (NYSE:GLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gelesis (NYSE:GLS)
Historical Stock Chart
From Apr 2023 to Apr 2024